Abstract
Summary
This study evaluated the 18-month persistence with teriparatide in 5413 postmenopausal osteoporotic women who were enrolled in an education and follow-up program. Analysis showed that the persistence rate was 81.5% for women who follow the program, higher than for existing oral antiresorptive treatments.
Introduction
An education and follow-up program was developed after launch of teriparatide in France in September 2004, to help women to follow the treatment. The objective of this study was to evaluate the persistence with teriparatide in postmenopausal osteoporotic women following this program.
Methods
Data about persistence are available for the period September 2004 to June 2007. Persistence is defined as the percentage of patients still on treatment at the end of the 18-month course, and it has been compared to the data provided by the French universal health insurance system.
Results
Since the launch of teriparatide in France in September 2004, 5413 postmenopausal women (mean age 72.3 ± 14.5 years) with osteoporosis and vertebral fractures (mean 3.9 ± 2) have participated in the program. The persistence rate at 15 months was 81.5%, and our analysis suggested that a majority of patients completed the 18-month treatment course. The main reason for discontinuation was adverse events (46.7%). Data of the French Universal Health Insurance suggest that the persistence may be close to 0% for women who are not in the program.
Conclusions
Postmenopausal osteoporotic women treated by teriparatide and enrolled in an education and follow-up program have a high persistence rate.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Cooper C (1997) The crippling consequences of fractures and their impact on quality of life. Am J Med 103:12S–17S
Oleksik A, Lips P, Dawson A et al (2000) Health-related quality of life in postmenopausal women with low BMD with or without prevalent vertebral fractures. J Bone Miner Res 15:1384–1392
Miller NH (1997) Compliance with treatment regimens in chronic asymptomatic diseases. Am J Med 102:43–49
Tosteson AN, Grove MR, Hammond CS et al (2003) Early discontinuation of treatment for osteoporosis. Am J Med 115:209–216
McCombs JS, Thiebaud P, McLaughlin-Miley C et al (2004) Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 48:271–287
Caro JJ, Ishak KJ, Huybrechts KF et al (2004) The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 15:1003–1008
Yood RA, Emani S, Reed JI et al (2003) Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int 14:965–968
Weycker D, Macarios D, Edelsberg J et al (2007) Compliance with osteoporosis drug therapy and risk of fracture. Osteoporos Int 18:271–277
Siris ES, Harris ST, Rosen CJ et al (2006) Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81:1013–1022
Rossini M, Bianchi G, Di Munno O et al (2006) Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int 17:914–921
Neer RM, Arnaud CD, Zanchetta JR et al (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441
Arden NK, Earl S, Fisher DJ et al (2006) Persistence with teriparatide in patients with osteoporosis: the UK experience. Osteoporos Int 17:1626–1629
Cramer JA, Gold DT, Silverman S, Lewiecki EM (2007) A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 18:1023–1031
Turbi C, Herrero-Beaumont G, Acebes JC et al (2004) Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: An open-label, prospective, nonrandomized, observational study. Clin Ther 26:245–256
Clowes JA, Peel NF, Eastell R (2004) The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 89:1117–1123
McLellan AR, Gallacher SJ, Fraser M, McQuillian C (2003) The fracture liaison service: success of a program for the evaluation and management of patients with osteoporotic fracture. Osteoporos Int 14:1028–1034
Lee JK, Grace KA, Taylor AJ (2006) Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial. JAMA 296:2563–2571
Delmas PD, Vrijens B, Eastell R et al (2007) Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 92:1296–1304
Cramer JA, Silverman SL, Gold DT (2007) Methodological considerations in using claims databases to evaluate persistence with bisphosphonates fro osteoporosis. Curr Med Res Opin 23:2369–2377
Acknowledgements
We thank Monique Weber, Jocelyn Courtois and Hubert Allemand (CNAMTS, Paris, France).
Conflicts of interest
Dr. S. Liu-Leage is an employee of Lilly Company. M. Zylberman is an employee of Lilly Company. All other authors state that they have no conflicts of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Briot, K., Ravaud, P., Dargent-Molina, P. et al. Persistence with teriparatide in postmenopausal osteoporosis; impact of a patient education and follow-up program: the French experience. Osteoporos Int 20, 625–630 (2009). https://doi.org/10.1007/s00198-008-0698-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00198-008-0698-8